title: Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma.
abstract: BACKGROUND
  This study was undertaken to measure survival of patients with multicystic peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy through a multi-institutional collaboration.
  
  
  METHODS
  A multi-institutional data registry, established by the Peritoneal Surface Oncology Group, was used to identify patients with peritoneal mesothelioma and the subgroup with multicystic tumours, treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Outcomes for this subgroup are reported. The primary endpoint was overall survival. A secondary endpoint was the incidence of treatment-related complications.
  
  
  RESULTS
  Of 405 patients with peritoneal mesothelioma, 26 (6·4 per cent) had multicystic tumours. There were 20 women and six men with a mean(s.d.) age of 42(12) years. The median peritoneal carcinomatosis index (PCI) was 14 (range 6-39). There was no perioperative mortality. Six patients developed grade III or IV complications. After a median follow-up of 54 (range 5-129) months, all 26 patients were still alive.
  
  
  CONCLUSIONS
  Multicystic peritoneal mesothelioma appears to be a distinct subtype of peritoneal mesothelioma, where long-term survival may be achieved through cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
authors.affiliation: University of New South Wales Department of Surgery, St George Hospital, Sydney, New South Wales, Australia.
authors.forename: T C
authors.initials: TC
authors.lastname: Chua
authors.forename: T D
authors.initials: TD
authors.lastname: Yan
authors.forename: M
authors.initials: M
authors.lastname: Deraco
authors.forename: O
authors.initials: O
authors.lastname: Glehen
authors.forename: B J
authors.initials: BJ
authors.lastname: Moran
authors.forename: P H
authors.initials: PH
authors.lastname: Sugarbaker
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy / Q000379:methods; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D053208:Kaplan-Meier Estimate; D007902:Length of Stay; D008297:Male; D018261:Mesothelioma, Cystic / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D010534:Peritoneal Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*
chemical_list: D004317:Doxorubicin; D017239:Paclitaxel; D002945:Cisplatin